PREDICTION-ADR partner Asper Biotech is working on the implementation of new reliable and validated testing panels to predict the side effects of statins and ACE inhibitors. Asper’s new testing portfolio – Asper Cardiogenetics – launched in 2015 – offers among other options risk assessment for developing adverse drug reactions, namely statin-induced myopathy. Currently the validated test includes targeted mutation analysis of the SLCO1B1 gene. In addition to the prediction of drug side effects, the test is beneficial for optimizing the statin dose. The initial test has been implemented within the PREDICTION-ADR project.
You may also like
The first newsletter of the PREDICTION-ADR consortium has been published. Read about the recent annual plenary meeting of the consortium held in […]
The second newsletter of the PREDICTION-ADR consortium has been published. Read about the recent annual plenary meeting of the consortium held in […]
Around 10% of individuals taking ACE inhibitors (ACEI) to control blood pressure will develop a persistent dry cough. This leads to inappropriate […]